Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma
Details : 123-I ATT001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : ATD-001
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ariceum Therapeutics
Deal Size : $44.0 million
Deal Type : Acquisition
Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
Details : The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets including, AT-001, a I-123-labelled PARP inhibitor for the treatment of aggressively growing cancers and it has UK ILAP approval for primary and recurrent gl...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $2.5 million
June 01, 2023
Lead Product(s) : ATD-001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ariceum Therapeutics
Deal Size : $44.0 million
Deal Type : Acquisition
Details : 68-Ga THP-PSMA is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
August 06, 2018
Reset All
